secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001104659-26-055241
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q1 net loss $88.6M; cash $666.7M; AXPAXLI NDA on track with SOL-1 data
--------------------------------------------------------------------------------

- Net loss $88.6M ($0.40 per share) vs $64.1M ($0.38) in Q1 2025; revenue $10.8M, up 0.8%.
- Cash $666.7M as of March 31, 2026; runway into 2028 excluding full AXPAXLI commercialization costs.
- AXPAXLI NDA for wet AMD on track based on SOL-1 Week 52 data; subject to FDA discussions; 505(b)(2) pathway may shorten review.
- SOL-1 positive: superior visual outcomes (74.1% maintained vision at Week 36 vs 55.8% aflibercept); p=0.0006 primary endpoint.
- SOL-R non-inferiority trial on track for topline 1Q 2027; HELIOS-3 ongoing; Investor Day June 17, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/0001104659-26-055241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-055241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer